Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
2.170
+0.070 (3.33%)
At close: Jan 22, 2026, 4:00 PM EST
2.190
+0.020 (0.92%)
After-hours: Jan 22, 2026, 7:58 PM EST
Biodexa Pharmaceuticals Revenue
Biodexa Pharmaceuticals had revenue of 13.50K GBP in the half year ending June 30, 2025.
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
1.82M USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 381.00K | -318.00K | -45.49% |
| Dec 31, 2022 | 699.00K | 654.62K | 1,475.10% |
| Feb 28, 2022 | 44.38K | -533.62K | -92.32% |
| Dec 31, 2021 | 578.00K | -4.02M | -87.43% |
| Feb 28, 2021 | 4.60M | 4.25M | 1,240.44% |
| Dec 31, 2020 | 343.00K | -331.00K | -49.11% |
| Dec 31, 2019 | 674.00K | -1.26M | -65.22% |
| Dec 31, 2018 | 1.94M | 949.00K | 95.96% |
| Dec 31, 2017 | 989.00K | -334.00K | -25.25% |
| Dec 31, 2016 | 1.32M | -52.00K | -3.78% |
| Dec 31, 2015 | 1.38M | 1.22M | 775.80% |
| Dec 31, 2014 | 157.00K | 10.00K | 6.80% |
| Dec 31, 2013 | 147.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| Ensysce Biosciences | 4.49M |
| Onconetix | 1.22M |
| Scinai Immunotherapeutics | 1.15M |
| Azitra | 7.50K |
| Aditxt | 5.95K |
| Virax Biolabs Group | 2.99K |
BDRX News
- 17 days ago - Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary - GlobeNewsWire
- 5 weeks ago - Biodexa Announces Pricing of $10 Million Public Offering - GlobeNewsWire
- 7 weeks ago - Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP - GlobeNewsWire
- 2 months ago - Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP - GlobeNewsWire
- 2 months ago - Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion - GlobeNewsWire
- 3 months ago - Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025 - GlobeNewsWire
- 4 months ago - Interim results for the six months ended June 30, 2025 - GlobeNewsWire
- 4 months ago - Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled - Accesswire